findmyKOL

Harrison Farber, MD

Enriched profile

Professor of Medicine; Director, Pulmonary Embolism Response Team (PERT), Pulmonary Hypertension Center · Tufts Medical Center

ORCIDNPI
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding1985–2015

Harrison Farber is Professor of Medicine; Director, Pulmonary Embolism Response Team (PERT), Pulmonary Hypertension Center at Tufts Medical Center. OpenAlex indexes 471 publications with 19,363 citations (h-index 59); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Harrison W. Farber, MD, is Professor of Medicine at Tufts Medical Center / Tufts University School of Medicine. The public record shows 471 publications with 19,363 citations (h-index 59), centered on Respiratory. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 38 companies, 6 NIH-funded awards (1985–2015).

  • Most recent indexed publication: 2025 · Pulmonary therapy
  • Top research focus: Respiratory
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 38 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Hypertension2 trialsPulmonary Hypertension2 trialsVentricular Dysfunction, Left1 trialVentricular Dysfunction1 trial

Research focus

OpenAlex concept fingerprint
Respiratory

Drugs & molecules

across trials, industry payments and publications
Uptravigeneric · SelexipagClinical trialsIndustry payments71Publications1Winrevairgeneric · SotaterceptClinical trialsIndustry payments9Publications1Tyvasogeneric · TreprostinilClinical trialsIndustry payments66Publications

Works with

trial sponsors and companies reporting payments
Actelion Pharmaceuticals US, Inc.Clinical trialsIndustry payments125United Therapeutics CorporationClinical trialsIndustry payments46Bayer HealthCare Pharmaceuticals Inc.Clinical trialsIndustry payments35

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
471publications

Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.

19,363citations

Total citations across indexed works.

59h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
38companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
6NIH grants · 1985–2015

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    48.9%
    Endothelin Receptor Antagonist27.7%
    Ambrisentan62%Opsumit25%Opsynvi13%
    Part D36 patients
    Loop diuretic9.3%
    Furosemide72%Torsemide28%
    Part D36 patients
  • Genitourinary & hormones

    25.8%
    Phosphodiesterase 5 Inhibitor25.8%
    Tadalafil68%Sildenafil Citrate15%Alyq10%Adcirca7%
    Part D<11 patients
  • Blood & clotting

    14%
    Prostacyclin Receptor Agonist6.1%
    Uptravi100%
    Part D17 patients
    Prostacycline Vasodilator5.9%
    Tyvaso Dpi65%Orenitram Er35%
    Part D<11 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)95.6% facility · 4.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

6 NIH research awards on record, funded 19852015 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/harrison-farber-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • Other

    profiles.bumc.bu.edu/ProfileDetails.aspx

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.bumc.bu.edu
  • Other

    bmc.org/findaphysician/PhysicianProfile.php

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bmc.org
3 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/phaware-global-association_im-aware-that-im-rare-the-phaware-podcast-activity-7117526165384286208-wnlq

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    teamphenomenalhope.org/about-us/board-of-directors

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →teamphenomenalhope.org
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    George Washington University School of Medicine and Health Sciences

    1977
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Board Certified

    Internal Medicine (American Board of Internal Medicine)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Board Certified

    Pulmonary Disease (American Board of Internal Medicine)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Editorial & leadership roles

journal and society appointments
  • Director

    Pulmonary Embolism Response Team (PERT), Tufts Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →teamphenomenalhope.org
  • Co-Director

    Pulmonary Hypertension Center, Tufts Medical Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tuftsphupdate.com
  • Professor of Medicine

    Tufts University School of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bumc.bu.edu

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.